US 11,744,830 B2
Ameliorative agent for cytokine release syndrome and so on
Yoshihiro Watanabe, Tokyo (JP); Yoshio Tahara, Tokyo (JP); Keisuke Suzuki, Tokyo (JP); Takayuki Mimura, Tokyo (JP); and Saori Ohmae, Tokyo (JP)
Assigned to TORII PHARMACEUTICAL CO., LTD., Tokyo (JP)
Appl. No. 17/53,179
Filed by TORII PHARMACEUTICAL CO., LTD., Tokyo (JP)
PCT Filed Nov. 29, 2019, PCT No. PCT/JP2019/046689
§ 371(c)(1), (2) Date Nov. 5, 2020,
PCT Pub. No. WO2020/111212, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 2018-223377 (JP), filed on Nov. 29, 2018; and application No. 2019-165013 (JP), filed on Sep. 11, 2019.
Prior Publication US 2021/0128550 A1, May 6, 2021
Int. Cl. A61K 31/495 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/495 (2013.01) [A61P 37/06 (2018.01)] 4 Claims
 
1. A method for treating or ameliorating cytokine release syndrome (CRS) that does not respond to tocilizumab, wherein the method comprises:
administering to a patient in need thereof an effective amount of a compound represented by the following formula II:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.